{"id":969644,"date":"2026-06-02T14:54:29","date_gmt":"2026-06-02T18:54:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/"},"modified":"2026-06-02T14:54:29","modified_gmt":"2026-06-02T18:54:29","slug":"kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/","title":{"rendered":"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm"},"content":{"rendered":"
\n

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)<\/u><\/strong> breached their fiduciary duties to shareholders.<\/p>\n

According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab\u2019s potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.<\/p>\n

If you currently own RARE and purchased prior to August 03, 2023 <\/strong>please contact\u00a0Justin Kuehn, Esq. by email at\u00a0justin@kuehn.law<\/a> or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients.<\/strong>Shareholders should contact the firm immediately as there may be limited time to enforce your rights.<\/em><\/p>\n

\n Why Your Participation Matters:<\/strong>\n <\/p>\n

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.<\/em>\u2122<\/p>\n

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law<\/a>.<\/p>\n

Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law<\/a>
(833) 672-0814<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab\u2019s potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates. If you currently own RARE and purchased prior to August 03, 2023 please contact\u00a0Justin Kuehn, Esq. by email at\u00a0justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs … <\/p>\n

Continue reading “Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-969644","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab\u2019s potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates. If you currently own RARE and purchased prior to August 03, 2023 please contact\u00a0Justin Kuehn, Esq. by email at\u00a0justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs … Continue reading "Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T18:54:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm\",\"datePublished\":\"2026-06-02T18:54:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/\"},\"wordCount\":221,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/\",\"name\":\"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=\",\"datePublished\":\"2026-06-02T18:54:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/","og_locale":"en_US","og_type":"article","og_title":"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Market Newsdesk","og_description":"NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab\u2019s potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates. If you currently own RARE and purchased prior to August 03, 2023 please contact\u00a0Justin Kuehn, Esq. by email at\u00a0justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs … Continue reading \"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-02T18:54:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm","datePublished":"2026-06-02T18:54:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/"},"wordCount":221,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/","name":"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=","datePublished":"2026-06-02T18:54:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDYxNSM3NjMzMDY1IzIyODUyNTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=969644"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969644\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=969644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=969644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=969644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}